Get started
Author

Taisuke Hoshi

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
2018 · Masahiro Matsuki, Taisuke Hoshi, et al. · Cancer Medicine · 266
PDF
Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR–MAPK cascades
2019 · Taisuke Hoshi, Saori Watanabe Miyano, et al. · Biochemical and Biophysical Research Communications · 79
PDF
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
2017 · Masahiro Matsuki, Yusuke Adachi, et al. · Cancer Science · 65
PDF
The MuSK activator agrin has a separate role essential for postnatal maintenance of neuromuscular synapses
2014 · Tohru Tezuka, Akane Inoue, et al. · Proceedings of the National Academy of Sciences · 55
PDF
The Effect of Resveratrol on the Werner Syndrome RecQ Helicase Gene and Telomerase Activity
2011 · Fumiaki Uchiumi, Takeshi Watanabe, et al. · Current Aging Science · 33
Mesdc2 plays a key role in cell‐surface expression of Lrp4 and postsynaptic specialization in myotubes
2013 · Taisuke Hoshi, Tohru Tezuka, et al. · FEBS Letters · 20
PDF
Cell-free DNA–based inference of the activities of 370 + transcription factors mirrors their activities in tumors
2025 · Ryuji Tamaki, Koji Sagane, et al. · BMC Genomics · 3
PDF
Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC)
2024 · Oneeb Majid, Seiichi Hayato, et al. · CPT Pharmacometrics & Systems Pharmacology · 3
Abstract 3264: Lenvatinib in combination with everolimus demonstrated enhanced antiangiogenesis and antitumor activity in human RCC xenograft models
2016 · Yusuke Adachi, Masahiro Matsuki, et al. · Cancer Research · 3
A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma
2026 · Masafumi Ikeda, Masatoshi Kudo, et al. · Liver Cancer · 2
PDF
Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).
2021 · Andrew X. Zhu, Josep M Llovet, et al. · Journal of Clinical Oncology · 2
ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.
2024 · T.R. Jeffry Evans, Masatoshi Kudo, et al. · Journal of Clinical Oncology · 1
PDF
Abstract 2976: Targeting fibroblast growth factor (FGF) signals induced type I IFN regulated response and Immunogenic cell death (ICD) markers in tumor cells with activated FGF signals
2020 · Taisuke Hoshi, Yu Kato, et al. · Cancer Research · 1
Abstract 3262: Effects of lenvatinib mesilate in combination with everolimus on VEGF and FGF-driven angiogenesis and tumor growth
2016 · Kaoru Mitsuhashi, Takayuki Kimura, et al. · Cancer Research · 1
Abstract 5899: Comparative analysis of transcription factor activities derived from low-pass whole genome sequencing of cell-free DNA and from ATAC-sequencing of tumors
2025 · Ryuji Tamaki, Koji Sagane, et al. · Cancer Research
Abstract 190: Lenvatinib induced cell death of cultured human hepatocellular carcinoma (HCC) under nutrient-starved condition through inhibition of FGFR signaling pathway
2019 · Taisuke Hoshi, Saori Watanabe Miyano, et al. · Tumor Biology
Abstract 190: Lenvatinib induced cell death of cultured human hepatocellular carcinoma (HCC) under nutrient-starved condition through inhibition of FGFR signaling pathway
2019 · Taisuke Hoshi, Saori Watanabe Miyano, et al. · Cancer Research
Abstract B095: Antitumor activity of lenvatinib mesilate (LEN) via angiogenesis inhibition and tumor FGF signaling pathway in the human hepatocellular carcinoma models
2018 · Taisuke Hoshi, Masahiro Matsuki, et al. · Molecular Cancer Therapeutics
Abstract 1805: Antitumor activity of lenvatinib mesilate in human hepatocellular carcinoma preclinical models
2017 · Masahiro Matsuki, Yuji Yamamoto, et al. · Cancer Research
Works count: 19
Citation count: 534
H-index: 6
I10-index: 6
Year
Topic
Type